RxDoctor Payments Data

Anna Dymala, MD

Family Medicine · Moline, ILNPI 1295121358

Payments from drug & device makers

$996in general payments, 2019–2025

Across 47 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$218
  • GSK$167
  • Lilly USA, LLC$128
  • Johnson & Johnson$119
  • Novo Nordisk$106
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$57
  • plus $202 from 7 others

What the payments were for

  • Food & beverage$996100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$996 in reported general payments places this provider in the 70th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$79,722
Medicare patients
119
Services billed
1,596

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$139,186
JardianceEmpagliflozin97$129,985
MounjaroTirzepatide62$91,962
TrulicityDulaglutide66$77,288
LinzessLinaclotide39$45,661
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$42,770
FarxigaDapagliflozin Propanediol15$24,620
EliquisApixaban29$24,295
RybelsusSemaglutide12$21,304
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr36$16,103
TradjentaLinagliptin21$14,861
Tresiba Flextouch U-200Insulin Degludec11$12,098
Spiriva RespimatTiotropium Bromide19$10,252
Breo ElliptaFluticasone/Vilanterol24$10,063
JanuviaSitagliptin Phosphate15$9,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$128$169,250128 claims
Novo NordiskOzempic, Rybelsus$106$160,48990 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$41$155,098137 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$167$71,962119 claims
AbbVieLinzess$218$45,66139 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$14$39,05743 claims
PfizerEliquis$53$24,29529 claims
MerckJanuvia$11$9,19515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Moline

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →